A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
A triplet did worse than control in first-line kidney cancer.
US approval could mark the company's graduation to oncology.
The FDA will rule on a low dose of zongertinib in the summer.
Meanwhile, Tango tries again in PRMT5.
Halda, Accent and Vividion take more projects into phase 1.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
